Angiogenesis and/or co-option of normal vessels plays a crucial role in gastrointestinal tumor development, growth, metastatic spread, and survival. For this reason, tumor-driven angiogenesis represents one of the most important therapeutic targets for the treatment of advanced gastrointestinal cancer. A consistent number of anti-angiogenic agents have been developed and are now available for these patients across different lines of treatment. Unfortunately, not all patients respond to anti-angiogenic drugs and some of them develop resistance, thus experiencing unnecessary potential toxicities. To date, despite extensive research, no validated clinical/translational predictive factors to identify patients who are more likely to positively respond to anti-angiogenic treatment are available. Therefore, identifying predictive factors is essential for optimizing treatment potentialities, avoiding unnecessary toxicities, and improving patients’ survival.
The goal of this Research Topic is to explore the complex landscape of tumor-driven angiogenesis and non-angiogenic growth in gastrointestinal malignancies, as well as potential biomarkers for anti-angiogenic agents, and to provide new evidence on the identification of clinical and translational prognostic and predictive factors in this setting, in order to improve patients’ selection for anti-angiogenic treatments and thus their clinical outcomes. We aim to provide a deeper understanding of the mechanisms of resistance to anti-angiogenic drugs in gastrointestinal cancer and resources to overcome treatment resistance. The assessment of these key points should focus on the state of the art of anti-angiogenic treatment in gastrointestinal tumors, on new evidence, and on future clinical and translational perspectives, from a precision medicine point of view.
In this Research Topic, we welcome Original Research Articles and Reviews Articles that explore, but are not limited to, the following:
- Angiogenesis and vascular co-option landscape in gastrointestinal tumors
- Targeting angiogenesis and/or vascular co-option in gastrointestinal cancer
- Clinical and translational biomarkers for efficacy and/or safety of anti-angiogenic agents in gastrointestinal malignancies
- Mechanisms of resistance to anti-angiogenic treatment in gastrointestinal tumors
- Innovative combinations of anti-angiogenic drugs and other agents for the treatment of gastrointestinal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Angiogenesis and/or co-option of normal vessels plays a crucial role in gastrointestinal tumor development, growth, metastatic spread, and survival. For this reason, tumor-driven angiogenesis represents one of the most important therapeutic targets for the treatment of advanced gastrointestinal cancer. A consistent number of anti-angiogenic agents have been developed and are now available for these patients across different lines of treatment. Unfortunately, not all patients respond to anti-angiogenic drugs and some of them develop resistance, thus experiencing unnecessary potential toxicities. To date, despite extensive research, no validated clinical/translational predictive factors to identify patients who are more likely to positively respond to anti-angiogenic treatment are available. Therefore, identifying predictive factors is essential for optimizing treatment potentialities, avoiding unnecessary toxicities, and improving patients’ survival.
The goal of this Research Topic is to explore the complex landscape of tumor-driven angiogenesis and non-angiogenic growth in gastrointestinal malignancies, as well as potential biomarkers for anti-angiogenic agents, and to provide new evidence on the identification of clinical and translational prognostic and predictive factors in this setting, in order to improve patients’ selection for anti-angiogenic treatments and thus their clinical outcomes. We aim to provide a deeper understanding of the mechanisms of resistance to anti-angiogenic drugs in gastrointestinal cancer and resources to overcome treatment resistance. The assessment of these key points should focus on the state of the art of anti-angiogenic treatment in gastrointestinal tumors, on new evidence, and on future clinical and translational perspectives, from a precision medicine point of view.
In this Research Topic, we welcome Original Research Articles and Reviews Articles that explore, but are not limited to, the following:
- Angiogenesis and vascular co-option landscape in gastrointestinal tumors
- Targeting angiogenesis and/or vascular co-option in gastrointestinal cancer
- Clinical and translational biomarkers for efficacy and/or safety of anti-angiogenic agents in gastrointestinal malignancies
- Mechanisms of resistance to anti-angiogenic treatment in gastrointestinal tumors
- Innovative combinations of anti-angiogenic drugs and other agents for the treatment of gastrointestinal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.